Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 姚凯诗教授 (药剂学院) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1517/14656560802413486 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/3WOS source URL
其它资讯
摘要Background: Entecavir is a new antiviral agent for chronic hepatitis B virus (HBV) infection with potent HBV suppression and a low rate of viral resistance. Objective: To review published studies on the pharmacoeconomics of entecavir for treatment of chronic HBV. Methods: A literature search on Medline and Embase over the period of 1998 - 2008 was performed in April 2008 using keywords 'entecavir' and 'cost'. Results/conclusion: Four studies comparing the cost effectiveness of entecavir with lamivudine and/or adefovir for treatment with chronic HBV infection using either decision tree or Markov modeling were reviewed. All four studies showed that entecavir was cost-effective in the treatment of chronic HBV with the incremental cost per QALY (quality-adjusted life-year) gained below the commonly accepted benchmark. The results are mainly due to the lower complication rates and better quality of life of patients using entecavir which can offset the higher acquisition cost of the drug. Patient characteristics, comparing agents and model assumptions were different among the four studies and they should be taken into account when applying the results to real life situations.
着者You JHS, Chan FWH
期刊名称EXPERT OPINION ON PHARMACOTHERAPY
出版年份2008
月份10
日期1
卷号9
期次15
出版社Taylor & Francis: STM, Behavioural Science and Public Health Titles
页次267http://aims.cuhk.edu.hk/converis/portal/Publication/3 - 2681
国际标準期刊号1465-6566
电子国际标準期刊号1744-7666
语言英式英语
关键词chronic hepatitis B; cost; cost-effectiveness; entecavir; pharmacoeconomics
Web of Science 学科类别Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY
